Seeing Through Skin, Barely

The second near-infrared window (NIR-II, 1000-1700 nm) allows light to penetrate several centimeters into biological tissue with dramatically reduced scattering and autofluorescence compared to visible light, potentially enabling real-time, non-invasive imaging of tumors, vasculature, and organ function at depths that current optical methods cannot reach. However, the lack of bright, biocompatible, and clinically translatable NIR-II fluorescent probes prevents this physics advantage from becoming a clinical tool. Existing NIR-II probes are either too dim (organic dyes), too toxic (quantum dots containing cadmium or lead), too large for renal clearance (carbon nanotubes), or too unstable in biological environments.

Surgical oncologists removing tumors currently rely on preoperative imaging (MRI, CT) and tactile feedback, with positive margins (cancer left behind) occurring in 20-40% of breast cancer and 15-30% of head and neck cancer surgeries. Real-time intraoperative imaging that could visualize tumor margins at depth would reduce re-excision rates, shorten surgeries, and improve patient outcomes. Beyond surgery, deep-tissue optical imaging could enable non-invasive monitoring of drug delivery, organ perfusion, and inflammatory processes without ionizing radiation, particularly valuable for pediatric patients and longitudinal monitoring.

Indocyanine green (ICG), the only FDA-approved NIR fluorophore, emits primarily in the NIR-I window (700-900 nm) and provides only superficial imaging (millimeters of depth). Quantum dots (PbS, CdSe/InAs) achieve excellent NIR-II brightness but contain heavy metals with known toxicity, blocking clinical translation. Single-walled carbon nanotubes have ideal emission wavelengths but their length (hundreds of nanometers) prevents renal clearance, raising accumulation and toxicity concerns. Small-molecule organic dyes with NIR-II emission have been developed but suffer from low quantum yields (typically <1%) and rapid photobleaching. Rare-earth nanoparticles (NaYF4:Er,Tm) show promise but require excitation at wavelengths that cause tissue heating. The fundamental tension is between achieving bright fluorescence at long wavelengths (which requires extended conjugation or heavy atoms) and maintaining biocompatibility and clearability (which favors small, simple molecules).

Discovery of a new class of NIR-II fluorophores that are simultaneously bright (quantum yield >5%), small enough for renal clearance (<6 nm hydrodynamic diameter), photostable, and composed of non-toxic elements. Alternatively, development of activatable or "turn-on" probes that are dim until they reach target tissue, enabling lower doses and reducing background. Advances in detector technology — particularly affordable, high-sensitivity InGaAs camera arrays — would also help by reducing the brightness requirements for probes.

A student team could systematically characterize the relationship between molecular structure and NIR-II quantum yield across a family of donor-acceptor-donor organic dyes, generating structure-property data that is currently lacking. Alternatively, a team could build a low-cost NIR-II imaging system using commercially available InGaAs sensors and benchmark its performance against visible-light fluorescence imaging in tissue phantoms. Relevant disciplines include materials science, chemistry, biomedical engineering, and optical engineering.